
A phase I study to assess the zzso dose zzso zzso toxicity zzso zzso zzso and zzso activity of zzso in combination with zzso in patients with advanced solid zzso 

Patients received zzso orally once daily on days zzso and zzso zzso on days 1, 4, 8 and 11 of a zzso zzso Starting dose zzso 1) was zzso zzso zzso and zzso zzso zzso zzso dosing was increased using a standard phase I zzso zzso zzso were evaluated during cycle zzso 

zzso patients received 57 cycles of treatment on four dose levels ranging from zzso zzso zzso to zzso zzso The zzso was established at zzso 400 zzso daily and zzso zzso zzso zzso consisted of grade 3 fatigue in three patients (1 zzso zzso and zzso zzso and grade 3 zzso in one patient zzso zzso The most common grade 1/2 zzso included zzso zzso fatigue zzso zzso zzso anorexia zzso and zzso zzso zzso partial responses were observed in one patient with zzso and in one patient with zzso soft tissue zzso zzso did not affect the zzso of zzso however, the zzso and zzso of the acid zzso were significantly increased on day 2 compared with day zzso 

This combination was generally zzso at doses that achieved clinical zzso The zzso was established at zzso 400 zzso daily zzso 14 days and zzso zzso zzso on days 1, 4, 8 and 11 of a zzso zzso 

